Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Health, Fitness & Food

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Products You May Like

Articles You May Like

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 
CVS CEO defends pharmacy middlemen, accuses drugmakers of ‘monopolistic’ practices
Chicken Tenders
UnitedHealth’s rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
The New HOKA BONDI 9 Just Raised The Comfort Bar (Again)

Leave a Reply

Your email address will not be published. Required fields are marked *